ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2018.1430761
Abstract: ABSTRACT Introduction: Approval of the HER2-targeted antibody trastuzumab dramatically improved outcomes for patients with HER2-positive breast cancer. Multiple trastuzumab biosimilars, including ABP 980, are in clinical development. Biosimilars are not identical to the reference biologic,… read more here.
Keywords: abp 980; trastuzumab; trastuzumab biosimilar; breast cancer ... See more keywords
Trastuzumab Biosimilar on Track for Approval.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-115
Abstract: An FDA expert panel recommended approval of Mylan's MYL-14010, a biosimilar candidate for Genentech's trastuzumab, putting it on track to become the first approved biosimilar for cancer. Experts predict that biosimilars will lead to lower… read more here.
Keywords: track; track approval; biosimilar track; trastuzumab biosimilar ... See more keywords
Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.557
Abstract: 557 Background: Although trastuzumab is generally well-tolerated, cardiotoxicity is the main limitation in its use, leading to a severe heart failure in 2-4% of patients in adjuvant trials. In the phase 3 LILAC trial, trastuzumab… read more here.
Keywords: cardiac safety; trastuzumab biosimilar; abp 980; safety ... See more keywords
Trastuzumab biosimilar in early breast cancer setting: will there be direct patient benefits?
Sign Up to like & getrecommendations! Published in 2017 at "Chinese clinical oncology"
DOI: 10.21037/cco.2017.10.03
Abstract: The inclusion of trastuzumab in the management of both early and metastatic HER2-positive breast cancer has significantly improved survival of these patients and is regarded as a standard of care. However, the cost of 12… read more here.
Keywords: breast cancer; biosimilar early; trastuzumab biosimilar; cancer ... See more keywords